Portage Biotech Announces 1-for-20 Reverse Stock Split
Portage Biotech (NASDAQ: PRTG) has announced a 1-for-20 reverse stock split of its ordinary shares, effective August 15, 2024. This strategic move aims to increase the per-share trading price and ensure compliance with Nasdaq's minimum $1.00 bid price requirement for continued listing. The split will convert every 20 pre-split shares into 1 post-split share, with fractional shares rounded up. Trading will continue under the symbol 'PRTG' with a new CUSIP number.
The reverse split will uniformly affect all shareholders, maintaining their percentage interest in the company, except for minor adjustments due to fractional shares. Outstanding options, warrants, and equity incentive plans will be adjusted accordingly. Notably, the number of authorized shares remains unlimited under British Virgin Islands law.
Portage Biotech (NASDAQ: PRTG) ha annunciato un consolidamento azionario 1-a-20 delle sue azioni ordinarie, che entrer脿 in vigore il 15 agosto 2024. Questa mossa strategica ha l'obiettivo di aumentare il prezzo di scambio per azione e garantire la conformit脿 al requisito minimo di $1.00 per il prezzo di offerta di Nasdaq per il mantenimento della quotazione. Il consolidamento convertir脿 ogni 20 azioni pre-consolidamento in 1 azione post-consolidamento, con le azioni frazionarie arrotondate per eccesso. La negoziazione continuer脿 sotto il simbolo 'PRTG' con un nuovo numero CUSIP.
Il consolidamento azionario influir脿 uniformemente su tutti gli azionisti, mantenendo la loro percentuale di interesse nell'azienda, eccetto per lievi aggiustamenti dovuti alle azioni frazionarie. Le opzioni in circolazione, i warrant e i piani di incentivazione azionaria saranno adeguati di conseguenza. 脠 importante notare che il numero di azioni autorizzate rimane illimitato secondo la legge delle Isole Vergini Britanniche.
Portage Biotech (NASDAQ: PRTG) ha anunciado un consolidaci贸n de acciones 1-a-20 de sus acciones ordinarias, que entrar谩 en vigor el 15 de agosto de 2024. Este movimiento estrat茅gico tiene como objetivo aumentar el precio de negociaci贸n por acci贸n y asegurar el cumplimiento del requisito m铆nimo de $1.00 para el precio de oferta de Nasdaq para mantener la lista. La consolidaci贸n convertir谩 cada 20 acciones antes de la consolidaci贸n en 1 acci贸n despu茅s de la consolidaci贸n, con las acciones fraccionarias redondeadas hacia arriba. La negociaci贸n continuar谩 bajo el s铆mbolo 'PRTG' con un nuevo n煤mero CUSIP.
La consolidaci贸n afectar谩 uniformemente a todos los accionistas, manteniendo su inter茅s porcentual en la empresa, excepto por ajustes menores debido a acciones fraccionarias. Las opciones en circulaci贸n, los warrants y los planes de incentivos de capital se ajustar谩n en consecuencia. Cabe destacar que el n煤mero de acciones autorizadas sigue siendo ilimitado bajo la ley de las Islas V铆rgenes Brit谩nicas.
韽嫲歆� 氚旍澊鞓ろ厤 (NASDAQ: PRTG)電� 1雽� 20 牍勳湪鞚� 欤检嫕 氤戫暕鞚� 2024雲� 8鞗� 15鞚茧秬韯� 鞁滍枆頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚� 鞝勲灥鞝� 臁办箻電� 欤茧嫻 瓯半灅 臧�瓴╈潉 雴掛澊瓿� 雮橃姢雼レ潣 斓滌唽 $1.00 鞛呾鞍 臧�瓴� 鞖旉惮 靷暛鞚� 欷�靾橅晿旮� 鞙勴暅 瓴冹瀰雼堧嫟. 氤戫暕鞚� 旮办〈鞚� 20欤茧ゼ 氤戫暕 頉� 1欤茧 鞝勴櫂頃橂┌, 攵勴暊霅� 欤检嫕鞚� 鞓 觳橂Μ霅╇媹雼�. 瓯半灅電� 'PRTG' 旮绊樃搿� 瓿勳啀 歆勴枆霅橂┌ 靸堧鞖� CUSIP 氩堩樃臧� 攵�鞐惄雼堧嫟.
牍勳湪 氤戫暕鞚� 氇摖 欤检＜鞐愱矊 瓿犽ゴ瓴� 鞓來枼鞚� 氙胳箻氅�, 須岇偓鞐� 雽�頃� 攴鸽摛鞚� 牍勳湪鞝� 鞚挫澋鞚� 鞙犾霅橃毵�, 攵勴暊霅� 欤检嫕鞙茧 鞚疙暅 氙胳劯 臁办爼鞚� 鞛堨姷雼堧嫟. 鞙犿毃頃� 鞓奠厴, 氤挫靹� 氚� 歆�攵� 鞚胳劶韹半笇 瓿勴殟霃� 鞚挫棎 霐半澕 臁办爼霅╇媹雼�. 欤茧頃� 鞝愳潃 鞓侁淡霠� 氩勳 鞝滊弰 氩曥棎 霐半澕 鞀轨澑霅� 欤检嫕 靾橁皜 氍挫牅頃滌溂搿� 鞙犾霅滊嫟電� 瓴冹瀰雼堧嫟.
Portage Biotech (NASDAQ: PRTG) a annonc茅 un rachat d'actions au ratio de 1 pour 20 de ses actions ordinaires, 脿 compter du 15 ao没t 2024. Ce mouvement strat茅gique vise 脿 augmenter le prix de n茅gociation par action et 脿 garantir le respect de l'exigence d'un prix d'offre minimum de 1,00 $ de Nasdaq pour un maintien de cotation. Le rachat convertira chaque 20 actions avant le rachat en 1 action apr猫s le rachat, les actions fractionnaires 茅tant arrondies 脿 l'unit茅 sup茅rieure. La n茅gociation se poursuivra sous le symbole 'PRTG' avec un nouveau num茅ro CUSIP.
Le rachat affectera uniform茅ment tous les actionnaires, maintenant leur pourcentage d'int茅r锚t dans l'entreprise, sauf pour de l茅gers ajustements dus aux actions fractionnaires. Les options en circulation, les bons de souscription et les plans d'incitation en capital seront ajust茅s en cons茅quence. 脌 noter que le nombre d'actions autoris茅es reste illimit茅 selon la loi des 脦les Vierges britanniques.
Portage Biotech (NASDAQ: PRTG) hat einen 1-zu-20 Reverse-Split seiner Stammaktien angek眉ndigt, der am 15. August 2024 wirksam wird. Dieser strategische Schritt zielt darauf ab, den Handelskurs pro Aktie zu erh枚hen und die Einhaltung der Mindestgebotsanforderung von $1,00 der Nasdaq f眉r eine weiterhin gelistete Aktie sicherzustellen. Der Split wird jede 20 vor dem Split gehaltene Aktie in 1 nach dem Split gehaltene Aktie umwandeln, wobei Bruchst眉cke aufgerundet werden. Der Handel wird weiterhin unter dem Symbol 'PRTG' mit einer neuen CUSIP-Nummer stattfinden.
Der Reverse-Split wird alle Aktion盲re einheitlich betreffen und ihren prozentualen Anteil am Unternehmen beibehalten, abgesehen von kleinen Anpassungen aufgrund von Bruchst眉cken. Ausstehende Optionen, Warrants und Aktienanreizpl盲ne werden entsprechend angepasst. Hervorzuheben ist, dass die Anzahl der genehmigten Aktien gem盲脽 dem Recht der Britischen Jungferninseln unbegrenzt bleibt.
- Aims to maintain Nasdaq listing compliance
- Potential increase in share price attractiveness to investors
- Indicates previous inability to maintain minimum share price
- May signal financial challenges or market perception issues
Insights
The 1-for-20 reverse stock split is a critical move for Portage Biotech to maintain its Nasdaq listing. This action will artificially boost the share price, potentially above the
Portage Biotech's reverse split reflects broader trends in the biotech sector, where many smaller companies struggle to maintain Nasdaq listings amid challenging market conditions. This move might temporarily solve the listing issue but doesn't address underlying challenges in the immuno-oncology space. Investor sentiment towards such actions is generally negative, often leading to increased scrutiny and potential sell-offs. However, if Portage can leverage this opportunity to refocus investor attention on its clinical-stage pipeline and novel therapies, it might mitigate some negative perceptions. The key will be demonstrating tangible progress in their multi-targeted therapies and securing partnerships or funding to advance clinical trials.
From a legal standpoint, Portage Biotech's reverse split adheres to regulatory requirements for maintaining Nasdaq listing. The company has properly disclosed the details, including the treatment of fractional shares and adjustments to outstanding securities. It's noteworthy that Portage, incorporated in the British Virgin Islands, has unlimited authorized shares, which differs from many U.S. corporations. This could provide flexibility for future capital raises but may also concern some investors about potential dilution. Shareholders should review their rights and any changes to voting power. While the split itself doesn't trigger legal issues, the company must ensure ongoing compliance with Nasdaq rules and SEC regulations to avoid future delisting risks.
WESTPORT, Conn., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (鈥淧ortage鈥� or the 鈥淐ompany鈥�) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of novel multi-targeted therapies for use as monotherapy and in combination, today announced that the Company鈥檚 Board of Directors approved a reverse stock split of its ordinary shares at a ratio of 1-for-20. Beginning with the opening of trading on August 15, 2024, Portage鈥檚 ordinary shares are expected to begin trading on The Nasdaq Capital Market on a split-adjusted basis under the existing trading symbol 鈥淧RTG鈥� and new CUSIP number G7185A136.
The reverse stock split is being implemented to increase the per share trading price of the Company鈥檚 ordinary shares for the purpose of ensuring a share price high enough to comply with the minimum
As a result of the reverse stock split, every twenty (20) pre-split ordinary shares will be converted into one (1) post-split ordinary share. Any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole post-split ordinary share. The reverse stock split affects all shareholders uniformly and will not alter any shareholder鈥檚 percentage interest in the Company鈥檚 ordinary shares, except for adjustments that may result from the treatment of fractional shares. All outstanding options and warrants entitling their holders to purchase the Company鈥檚 ordinary shares will be adjusted as a result of the reverse stock split, in accordance with the terms of each such security. In addition, the number of ordinary shares reserved for future issuance pursuant to the Company鈥檚 equity incentive plans will also be appropriately adjusted. The number of authorized ordinary shares will not be proportionately reduced because the Company has an unlimited number of authorized ordinary shares available for issuance, as permitted under the laws of the British Virgin Islands.
Portage鈥檚 transfer agent, TSX Trust Company, which is also acting as the exchange agent for the reverse stock split, will provide instructions to shareholders regarding the process for exchanging any share certificates.
About聽Portage Biotech Inc.听听听听听听听听
Portage is a clinical-stage immuno-oncology company advancing multi-targeted therapies to extend survival and significantly improve the lives of patients with cancer. The Company has made the decision to discontinue its sponsored trial for its the invariant natural killer T-cell (iNKT) program and pause patient enrollment to its sponsored adenosine trial program (ADPORT-601 trial) for its potentially best-in-class adenosine antagonists PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor). The Company is exploring strategic alternatives, which may include finding a partner for one or more of its assets, a sale of the company, a merger, restructurings, both in and out of court, a company wind down, further financing efforts or other strategic action. For more information, please visit , follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.
Forward-Looking Statements
All statements in this news release, other than statements of historical facts, including without limitation, statements regarding about the Company鈥檚 information that are forward-looking in nature and, business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise include the words "believe," "expects," "anticipates," "intends," "estimates," 鈥渨ill,鈥� 鈥渕ay,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥渃ontinue,鈥� or similar expressions or variations on such expressions are forward-looking statements. For example, statements regarding the reverse stock split and the timing thereof and expectations related thereto, and compliance with the minimum bid price requirement are forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company鈥檚 actual results to differ materially from the results described in or implied by the forward-looking statements. Factors that may cause the Company鈥檚 actual results to differ materially from those expressed or implied in the forward-looking statements in this news release are described in 鈥淚tem 3 - Key Information-Risk Factors鈥� in the Company鈥檚 Annual Report on Form 20-F for the year ended March 31, 2023. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations:
Media Relations:
FAQ
When will Portage Biotech's 1-for-20 reverse stock split take effect?
What is the new CUSIP number for Portage Biotech (PRTG) after the reverse split?
How will the reverse split affect Portage Biotech (PRTG) shareholders?
Why is Portage Biotech (PRTG) implementing a reverse stock split?
